Alpha Tau Medical Ltd (DRTS)
NASDAQ:DRTS
Want to see DRTS full AI Analyst Report?
DRTS Stock Chart & Stats
$8.03
$0.35(10.45%)
At close: 4:00 PM EST
$8.03
$0.35(10.45%)
Day’s Range― - ―
52-Week Range$2.85 - $11.62
Previous CloseN/A
Volume116.73K
Average Volume (3M)1.13M
Market Cap
$866.90M
Enterprise Value$959.04M
Total Cash (Recent Filing)$76.90M
Total Debt (Recent Filing)$13.73M
Price to Earnings (P/E)―
Beta0.94
Next Earnings
Aug 18, 2026EPS Estimate
-0.14Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.53
Shares Outstanding88,009,735
10 Day Avg. Volume1,247,552
30 Day Avg. Volume1,131,385
Financial Highlights & Ratios
PEG Ratio-0.53
Price to Book (P/B)5.17
Price to Sales (P/S)0.00
P/FCF Ratio-12.18
Enterprise Value/Market Cap1.11
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-22.75
Forecast
1Y Price Target
$13.50Price Target Upside68.12% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-0.62
Revenue Forecast (FY)$1.23M
Bulls Say, Bears Say
Bulls Say
Long-term U.S. Commercialization PartnershipA 20-year exclusive Tolmar collaboration supplies non-dilutive strategic capital ($15M manufacturing funding, $20M equity) and milestone payments, materially de-risking U.S. commercialization execution and funding manufacturing scale-up while leveraging an established commercial infrastructure for prostate oncology.
Pivotal Trial Progress And Positive Clinical DataCompletion of a U.S. pivotal study and multiple encouraging clinical readouts (pancreatic, glioblastoma) enhance regulatory pathways and evidence generation. Sustained positive trial momentum across indications strengthens the long-term potential for approvals and diversified clinical adoption in high‑need oncology markets.
Improved Balance Sheet And LiquidityTransition from prior negative equity to sizable positive equity and cash balances provides a multi‑quarter runway to fund pivotal studies and initial commercial build, reducing immediate financing pressure and enabling execution on regulatory and manufacturing milestones over the next several quarters.
Bears Say
Zero Reported RevenueAbsence of product revenue leaves the company reliant on financing events and future approvals; persistent annual losses magnify dilution risk and mean commercial scale and sustainable cash generation remain unproven absent regulatory approvals and successful market adoption.
Persistent Negative Operating Cash FlowSustained operating cash burn and declining free cash flow indicate ongoing reliance on external funding. If capital markets tighten or milestone payments lapse, the company could face constrained liquidity, slowing trials or commercialization timelines and increasing execution risk over the medium term.
Conservative U.S. Economics Via Partnership TermsExclusive long-term rights and a 60% purchase price structure could cap Alpha Tau’s U.S. gross margin and future revenue capture. Dependence on partner commercialization effectiveness and pricing mechanics may limit upside of U.S. launches and shift commercial execution risk to Tolmar.
Alpha Tau Medical Ltd News
DRTS FAQ
What was Alpha Tau Medical Ltd’s price range in the past 12 months?
Alpha Tau Medical Ltd lowest stock price was $2.85 and its highest was $11.62 in the past 12 months.
What is Alpha Tau Medical Ltd’s market cap?
Alpha Tau Medical Ltd’s market cap is $866.90M.
When is Alpha Tau Medical Ltd’s upcoming earnings report date?
Alpha Tau Medical Ltd’s upcoming earnings report date is Aug 18, 2026 which is in 63 days.
How were Alpha Tau Medical Ltd’s earnings last quarter?
Alpha Tau Medical Ltd released its earnings results on May 18, 2026. The company reported -$0.26 earnings per share for the quarter, missing the consensus estimate of -$0.124 by -$0.136.
Is Alpha Tau Medical Ltd overvalued?
According to Wall Street analysts Alpha Tau Medical Ltd’s price is currently Undervalued.
Does Alpha Tau Medical Ltd pay dividends?
Alpha Tau Medical Ltd does not currently pay dividends.
What is Alpha Tau Medical Ltd’s EPS estimate?
Alpha Tau Medical Ltd’s EPS estimate is -0.14.
How many shares outstanding does Alpha Tau Medical Ltd have?
Alpha Tau Medical Ltd has 88,009,735 shares outstanding.
What happened to Alpha Tau Medical Ltd’s price movement after its last earnings report?
Alpha Tau Medical Ltd reported an EPS of -$0.26 in its last earnings report, missing expectations of -$0.124. Following the earnings report the stock price went up 6.481%.
Which hedge fund is a major shareholder of Alpha Tau Medical Ltd?
Currently, no hedge funds are holding shares in DRTS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Alpha Tau Medical Ltd Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$13.50 (68.12% Upside)
$13.50 (68.12% Upside)
Blogger Sentiment
Bullish
DRTS Sentiment 70%
Sector Average ―
Sector Average ―
Insider Transactions
Sold Shares
Worth $352.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 0.9%
Last 30 Days ▲ 19.2%
Last 30 Days ▲ 19.2%
News Sentiment
Very Bullish
Bullish news 99%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
220.84%
12-Months-Change
Fundamentals
Return on Equity
-73.23%
Trailing 12-Months
Asset Growth
34.41%
Trailing 12-Months
Company Description
Alpha Tau Medical Ltd
Alpha Tau Medical Ltd. is a clinical-stage biotechnology company dedicated to the advancement and eventual commercialization of innovative cancer treatments. Their primary focus is on "Alpha DaRT" (Diffusing Alpha-Emitters Radiation Therapy), a novel approach designed to combat solid tumors. This therapeutic radiation technique is currently undergoing clinical evaluation for various solid malignancies, including skin, oral, pancreatic, and breast cancers, with development efforts primarily concentrated in Israel and the United States. Furthermore, Alpha DaRT is being explored in preclinical investigations for additional challenging cancers such as hepatic cell carcinoma, glioblastoma multiforme (a type of brain tumor), and lung cancer, among others. Established in 2015, the company maintains its headquarters in Jerusalem, Israel.
DRTS Stock 12 Month Forecast
Average Price Target
$13.50
▲(68.12% Upside)
Technical Analysis
Larimar Therapeutics
―
Capricor Therapeutics
―
Benitec Biopharma
―
Aura Biosciences Inc
―
Lexeo Therapeutics, Inc.
―
Ownership Overview
0.17% Insiders
0.05% Mutual Funds
2.32% Other Institutional Investors
97.10% Public Companies and
Individual Investors